The Journal of infection
-
The Journal of infection · Dec 2012
Randomized Controlled TrialRandomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305).
Evidence suggests that statins may modify the immune response against HIV. The aim was to evaluate the antiretroviral and immunomodulatory effects of lovastatin in HIV-infected patients, naïve for antiretroviral therapy. ⋯ Daily administration of lovastatin (40 mg) for one year in HIV-infected patients, naïve for antiretroviral therapy, had no significant effect on HIV replication, the CD4+ T cell count, or the activation level of T cells. (www.clinicaltrials.gov; ID NCT00721305).